One hundred and eighty adult patients candidate to chemotherapy were randomized into three groups : power-injectable PICCs with Solo-2 proximal valve ( Bard ) ; power-injectable PICCs with PASV ( Pressure Activated Safety Valve ) proximal valve ( Navilyst ) ; and non-valved power-injectable PICCs ( Medcomp ) .